Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 Testing in the Era of Modern Neurosurgery: Mitigating Risk in Our Vulnerable Patient Populations

Daniel M. Aaronson¹, David M. Poetker², Christopher M. Long², Nathan T. Zwagerman¹

BACKGROUND: The respiratory illness identified as coronavirus disease 2019 (COVID-19) has resulted in a pandemic illness that has changed the face of healthcare. As the COVID-19 pandemic continues, patients have continued to require neurosurgical interventions, and the endoscopic endonasal approach for surgery has continued to be a mainstay treatment of pituitary tumors and anterior skull base lesions.

METHODS: We sought to highlight the current lack of recommendations regarding testing protocols for neurosurgical patients.

RESULTS: We implemented a novel testing protocol for our patient populations at increased risk and have proposed a model that can be used at other institutions to mitigate the risk of complications associated with some forms of COVID-19 testing.

CONCLUSION: Patients with anterior skull base defects may be at risk with current COVID-19 testing protocols, and may benefit from alternative specimen collection strategies.

INTRODUCTION

The respiratory illness identified as coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO) in March 2020.¹ COVID-19 is caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). The Centers for Disease Control and Prevention (CDC) has identified >7 million cases with >200,000 deaths from COVID-19 as of September 29, 2020.² The demographics of the disease have continued to shift, with more recent reports showing increasing case counts in young adults.³ As the COVID-19 pandemic has continued, patients have continued to require neurosurgical interventions, and the endoscopic endonasal approach (EEA) for surgery has continued to be a mainstay treatment of pituitary tumors and anterior skull base lesions. We identified our EEA patients, in addition to other neurosurgical populations, as a subset of patients vulnerable to possible intracranial damage resulting from the current standards for COVID-19 testing. We then implemented a novel testing protocol for our patient populations at increased risk and have proposed a model that can be used at other institutions to reduce the risk of complications associated with COVID-19 testing.

CURRENT STRATEGIES AND TESTING PROTOCOL

Various public health strategies have been used by different countries in attempts to stem the spread of COVID-19. Paramount to most containment strategies has been the widespread availability of accurate testing.⁴-⁹ In the early stages of the COVID-19 pandemic, the CDC advised that the preferred method of specimen collection was the nasopharyngeal (NP) swab,¹⁰ with the recommendation echoed by the WHO.¹¹ By April 29, 2020, the CDC had altered the language of their guidelines for specimen collection to remove the preference for NP swabs and listing collection guidelines for nasal mid-turbinate (NMT) swabs and anterior nares (AN) specimens. As of October 8, 2020, the guidelines also included language for the collection of oral saliva specimens. The most current guidelines from the WHO still recommend a combined NP and oropharyngeal swab specimen for most patients.¹² At our own institution, NP swabs were still the standard of care for specimen collection in many patient settings, although the desire to switch to primary NMT swabs had been previously expressed.
CURRENT STATE OF THE LITERATURE

Existing studies of the COVID-19 pandemic in relation to patients undergoing anterior skull base surgery are sparse. The current literature in peer-reviewed journals has included descriptions of triaging of patients best treated with an EEA, 13-15 the recommended personal protective equipment for surgeons performing EEA surgery, 16-20 case reports of COVID-19–positive patients who had undergone an EEA, 21,22 a compendium of anecdotes from physician teams around the world, 23 and studies that sought to quantify the aerosolization patterns during endoscopic instrumentation. 24-26 To the best of our knowledge, no currently reported studies have described COVID-19 testing protocols nor highlighted the risks involved for patients who have previously undergone an EEA or have other anterior skull base defects.

DISCUSSION

COVID-19 is a global pandemic that has posed many unique challenges to the medical community and the world at large. As the rates have continued to increase in many areas of the world and as the capacity for testing has expanded, it has become clear that testing for COVID-19 has become a mainstay in our ability to provide medical care to our patients. Many hospitals routinely test for COVID-19 before all inpatient admissions and elective surgical procedures and for pregnant women admitted to labor and delivery units. 27,28 With no definite end to the pandemic in sight and uncertain timing regarding the widespread delivery of a vaccine in our future, we should expect COVID-19 testing to continue to be a part of routine patient care. Various testing methods exist, and although the best testing specimen collection strategy is still under debate, respiratory tract specimens have been shown to have the highest levels of detection of SARS-CoV-2. 29 Oral saliva samples are being examined more closely, and although the initial evaluations have been promising, 30-32 these tests have not been accepted for widespread use in most hospital settings.

With the current testing strategies in place, we must also be mindful of the anatomic considerations and possible complications of specimen collection test for COVID-19. The current NP collection recommendations from the CDC are to be performed “through the nostril parallel to the palate ... until resistance is encountered or the distance is equivalent to that from the ear to the nostril of the patient, indicating contact with the nasopharynx. The swab should reach a depth equal to the distance from the nostrils to the outer opening of the ear.” 33 With many tests performed still with NP collection, we theorized that this specimen collection method could result in the depth required to traverse the skull base and for the swab to cross into the intracranial space in the case of a patient with skull base defects. These defects could be congenital, acquired as the result of trauma or tumor erosion through bony structures, or iatrogenic through either nasal or skull base surgery. Injury can occur through the cribiform plate, sphenoid sinus, or, even, the clivus. Such injuries can result in a cerebrospinal fluid leak, parenchymal damage to brain tissue itself, or vascular damage, leading to hemorrhage or stroke.

We do not believe these concerns to be unfounded, because a strong record exists in the literature of intracranial complications resulting from intranasal interventions in the course of treatment for patients with skull base defects. These complications have usually resulted from inadvertent intracranial nasogastric tube insertion in patients who have either undergone an EEA 34-36 or other intranasal procedures 39 or after trauma with skull base fractures. 40,41 In the case of intracranial nasogastric insertion, however, the diagnosis can be made rapidly with intracranial imaging studies using either skull radiography or computed tomography, because the nasogastric tubes will usually be left in place. The additional danger with NP testing is that the injury can be caused transiently, with immediate removal of the offending foreign body, which could make detection and diagnosis more difficult. Close to the time of the submission of our article, the first case of a cerebrospinal leak as a result of routine COVID-19 testing before an elective surgery in a patient with a remote history of nasal surgery was reported. 42

It has been reported that significant rationing of neurosurgical services occurred at the onset of the pandemic, with ≤80% of institutions reporting a decrease in their ability to provide services, 43 with those centers with lower resources before the pandemic most affected. These included hospitals that reported an inability to provide neurosurgical care to all patients with legitimate medical need and, even, cases of neurosurgical emergencies that went untreated. 44-46 Owing to the ongoing need for neurosurgical care during the pandemic, in our tertiary care setting, which includes our level 1 trauma center, we implemented the following testing guidelines to mitigate the risk in our vulnerable patient populations and minimize the delay in medically indicated care:

1. Trauma patients who arrive intubated or are intubated soon after arrival who require routine testing before admission
   A. Should undergo only NMT, AN, or oral saliva testing per acceptable institutional protocols, unless the report of the computed tomography scan of the head is available and has excluded the diagnosis of skull base fractures
2. Trauma patients with confirmed skull base fractures
   A. Should undergo only NMT, AN, or oral saliva testing per acceptable institutional protocols
3. Postoperative anterior skull base patients and patients who have undergone EEA
   A. Should receive formal education on COVID-19 testing postoperatively
   B. No COVID-19 testing should be performed during the first 2 weeks after skull base surgery
4. After week 2, only NMT, AN, or oral saliva testing per acceptable institutional protocols should be used
5. After week 6, assuming complete healing has been confirmed via endoscopy, any test method is appropriate
4. Preoperative anterior skull base patients and patients who will undergo EEA with identified bony erosion
   A. Only NMT, AN, or oral saliva testing should be used per acceptable institutional protocols
5. In these patient populations with a high clinical suspicion of COVID-19 for whom a NP swab collection has been requested after NMT, AN, or oral saliva testing has resulted in a negative test
   A. Consultation should be made with a qualified ear, nose, and throat surgeon to consider performing NP testing under direct endoscopic visualization
CONCLUSIONS
As the COVID-19 pandemic continues to be a public health crisis, testing has continued to be paramount to management strategies. As testing has become more ubiquitous in multiple healthcare settings, it is imperative to identify and protect those patient populations that might be at risk of complications from some of the current specimen collection protocols for testing for COVID-19. We identified multiple patient populations that could have anterior skull base defects and recommend alternative specimen collection strategies, including NMT, anterior nasal, and/or oral saliva testing be used for these patients to prevent the serious complications that can arise.

CRediT AUTHORSHIP CONTRIBUTION STATEMENT
Daniel M. Aaronson: Conceptualization, Writing — original draft, Writing — review & editing. David M. Poetker: Writing — review & editing. Christopher M. Long: Writing — review & editing. Nathan T. Zwagerman: Supervision, Writing — review & editing.
nasopharyngeal swab for the detection of SARS-CoV-2 in symptomatic patients. J Clin Microbiol. 2020;58:e01946-20.

32. Rao M, Rashid FA, Sabri F, et al. Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2. Clin Infect Dis. 2021;e352-e356.

33. Centers for Disease Control and Prevention. Information for Laboratories About Coronavirus (COVID-19). Available at: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html. Accessed September 29, 2020.

34. Bhattacharyya N, Gopal HV. Examining the safety of nasogastric tube placement after endoscopic sinus surgery. Ann Otol Rhinol Laryngol. 1998;107:662-664.

35. Guerra B, Slade TL, Kelly PJ. Intracranial introduction of a nasogastric tube in a patient with a pituitary tumor. Surg Neurol. 1979;12:135-136.

36. Hande A, Nagpal R. Intracranial malposition of nasogastric tube following transnasal transsphenoidal operation. Br J Neurosurg. 1991;5:205-207.

37. Hanna AS, Grindle CR, Patel AA, Rosen MR, Evans JR. Inadvertent insertion of nasogastric tube into the brain stem and spinal cord after endoscopic skull base surgery. Am J Otolaryngol. 2012;33:178-180.

38. Zhang X, Li T, Chen L, Yang J, Huang G. Nasogastric tube feeding into brain after endoscopic endonasal transsphenoidal surgery. World Neurosurg. 2019;132:4-6.

39. Obiorah S, Moldovan K, Doberstein C. Intracranial insertion of a nasogastric tube following septoplasty: case report and literature review. Interdisciplinary Neurosurgery. 2020;22:100879.

40. Chandra R, Kumar P. Intracranial introduction of a nasogastric tube in a patient with severe craniofacial trauma. Neurol India. 2010;58:804-805.

41. Roka YB, Shrestha M, Puri PR, Aaral S. Fatal inadvertent intracranial insertion of a nasogastric tube. Neurol India. 2010;58:802-804.

42. Sullivan CB, Schwalje AT, Jensen M, et al. Cerebrospinal fluid leak after nasal swab testing for coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020;146:1173-1176.

43. Mathiesen T, Artaez M, Asser T, et al. A snapshot of European neurosurgery December 2019 vs. March 2020: just before and during the COVID-19 pandemic. Acta Neurochir. 2020;162:2221-2233.

Conflict of interest statement: The authors declare that the article content was composed in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received 31 March 2021; accepted 4 June 2021

Citation: World Neurosurg. (2021) 152:80-83. https://doi.org/10.1016/j.wneu.2021.06.027

Journal homepage: www.journals.elsevier.com/world-neurosurgery

Available online: www.sciencedirect.com

1878-8750/$ - see front matter © 2021 Elsevier Inc. All rights reserved.